Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      From Enrollment to Informed Consent, Nurses Are Vital in the Clinical Trial Process

      April 17, 2019
      By Brielle Benyon
      Article

      Oncology nurses are valuable players in enrolling patients in clinical trials, and then guiding them through the process — especially when it comes to complicated informed consent documents – explained Katie Goodman, RN, BSN, CCRP, the director of clinical research at Florida Cancer Specialists.

      “The oncology nurse plays a critical role in the management of patients on a clinical trial,” Goodman said in a recent interview with Oncology Nursing News.

      Oncology Nursing News: What role do oncology nurses play in clinical trial recruitment and support?

      Goodman: We feel that physicians will largely identify patients who are eligible for clinical trials, but the nurse will oftentimes facilitate the work that has to happen to get a patient on the trial. We follow the protocol to get baseline testing performed according to the protocol schedule, and then we really work to get the patient on the study.

      We educate the patients on the things they need to know. We will often go through the consent form page by page, which can sometimes be 10 or 15 pages long in oncology. The oncology nurse will spend a lot of time with the patients, making sure they truly understand that consent form and what's involved in the clinical trial.

      Once the patient enrolls, nurses will then also meet with them at nearly every visit to do things like review all of their current medications that they might be on, any side effects that they might be experiencing, and again helping the patient to manage any side effects that they have.

      What kind of issues might occur regarding the informed consent process?

      The informed consent process is a lengthy one. It usually requires multiple meetings with patients. The physician may often introduce the trial, but an oncology nurse is often the one who is sitting down and going through that consent on a more detailed level. For example, we need to make sure patients understand the numbers of visits that may be involved, so they understand that commitment. What kind of lab work will they be agreeing to? Is there additional lab work? For example, many studies will collect additional biomarkers or even biopsies or tissue samples that they want to perhaps use in later research and that patient has to understand that during the consent process so that they can make a decision on whether or not they want to participate.

      The consent process also involves the risks and benefits of participating in that trial. Patients need to understand what the potential risks are, and what are the potential benefits. What happens if they don't go on this trial? That's all a part of that consent process to make sure that they understand what they are committing to.

      What important information would you like to give oncology nurses regarding clinical trials?

      I hope that oncology nurses learn that they are a valued piece of that puzzle in getting patients on trials. I hope they learn to know how to better explain what a clinical trial means to a patient, where they can get their answers if they have questions, and how to find a clinical trial. Any oncology nurse or a patient can go to clinicaltrials.gov and really search and help identify potential trials or a center that might be participating in multiple trials that could have something to offer.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman wearing a patterned shirt in front of a dark blue background
      Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
      3 experts in this video
      3 experts in this video
      Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
      Related Content

      Graphic that resembles a stamp of approval reading "FDA Approved"

      FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

      Bridget Hoyt
      June 12th 2025
      Article

      The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Photo of the FDA building

      FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC

      Bridget Hoyt
      June 12th 2025
      Article

      UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic that resembles a stamp of approval reading "FDA Approved"

      Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer

      Bridget Hoyt
      June 11th 2025
      Article

      The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.


      Anatomical image of a person with a breast tumor

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      Tim Cortese
      June 11th 2025
      Article

      T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

      Related Content

      Graphic that resembles a stamp of approval reading "FDA Approved"

      FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

      Bridget Hoyt
      June 12th 2025
      Article

      The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Photo of the FDA building

      FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC

      Bridget Hoyt
      June 12th 2025
      Article

      UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic that resembles a stamp of approval reading "FDA Approved"

      Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer

      Bridget Hoyt
      June 11th 2025
      Article

      The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.


      Anatomical image of a person with a breast tumor

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      Tim Cortese
      June 11th 2025
      Article

      T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

      Latest Conference Coverage

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      Olanzapine May Reduce Nausea, Vomiting From Radiation

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.